ArticleFrontiers in aging neuroscience2026
Chronic nicotine reverses age-related decline of interneuron markers in mouse auditory cortex.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Inhibition in central auditory pathways declines in old age, which contributes to age-related auditory processing deficits. In auditory cortex, most inhibitory interneurons can be identified by one of three marker proteins: parvalbumin (PV), somatostatin (SOM), or vasoactive intestinal peptide (VIP). About 10% of interneurons contain the α2 nicotinic acetylcholine receptor (α2 cells), and most of these are layer 5 Martinotti cells (α2-MCs). We examined the distribution of these four interneuron subtypes in auditory cortex of FVB mice, from young adult through old age, and the extent to which α2 cells express the marker proteins. We also examined the effects of chronic nicotine exposure (CNE) at older ages, as a step toward potential therapeutic applications. We found that the numbers of cells expressing PV, SOM and VIP, and α2-MCs, all declined with age, but total α2 cells did not. We also found that most (86%) α2 cells in young adult mice co-expressed SOM, but the co-expression declined sharply with age. Notably, CNE for three months-starting at age 9, 15, or 21 months-increased the numbers of cells with PV and VIP at 12, 18, and 24 months, respectively, to levels seen in young adults. CNE increased SOM interneurons only at 12 months and had no effect on the number of α2 cells. An analysis of immunofluorescence intensity in 12-month-old mice suggested that the increase in cell counts after CNE resulted from increased expression of marker protein, rather than
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.